Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Lowered to "Hold" Rating by Wall Street Zen

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

Several other research analysts have also recently weighed in on KNSA. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals International Stock Down 1.6%

Shares of Kiniksa Pharmaceuticals International stock opened at $28.04 on Friday. Kiniksa Pharmaceuticals International has a 52 week low of $17.38 and a 52 week high of $30.69. The business has a 50 day moving average price of $26.79 and a 200-day moving average price of $22.63. The company has a market cap of $2.05 billion, a PE ratio of -112.16 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. Kiniksa Pharmaceuticals International's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) EPS. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity

In other news, COO Eben Tessari sold 45,042 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the transaction, the chief operating officer now owns 72,363 shares in the company, valued at approximately $2,207,795.13. This represents a 38.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ross Moat sold 64,035 shares of the company's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $25.21, for a total transaction of $1,614,322.35. Following the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $237,352.15. This trade represents a 87.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 440,863 shares of company stock valued at $12,101,029 in the last three months. Company insiders own 53.48% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KNSA. GAMMA Investing LLC grew its stake in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. US Bancorp DE bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at $33,000. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $41,000. Wealthquest Corp purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $61,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.